The diameters of pial vessels in the cat were measured through a closed cranial window after i.v. injection of dihydralazine (250 Mg or 1 mg-kg'). The intracranial pressure was recorded from a needle in the cisterna magna. In 7 cats given 1 mg'kg" 1 dihydralazine, arterial vessels with a resting diameter of 72 ± 24 nm (SD) dilated by 58 ± 21 % (p < 0.01), with no significant change seen in the reins. The intracranial pressure increased by 95 ± 30 %. The maximum increase in intracranlal pressure and arterial diameter was observed before the blood pressure had reached its lowest level. The dilatation far exceeded the autoregulatory dilatation observed at corresponding pressure reductions induced by bleeding. It is concluded that dihydralazine dilates pial arterial vessels.
HYDRALAZINE AND DIHYDRALAZINE have been shown to dilate precapillary resistance vessels but are considered to have little or no effect on systemic veins. 1 - 3 Based on a study of cerebral blood flow (CBF) and intracranial pressure (ICP) in some patients with neurological diseases, Overgaard and Skinh^j' concluded that, "hydralazine is a cerebral vasodilator acting first upon cerebral capacitance vessels but later upon the resistance vessels as well." However, the evidence for a dilatory effect on cerebral veins was indirect and in our opinion not conclusivethe interpretation of the results being particularly difficult since cerebral autoregulation was disturbed in most of the CBF studies. A better knowledge of the action of dihydralazine and hydralazine on cerebral vessels seems important, since drugs of this type are commonly used to decrease the blood pressure acutely in neurological and neurosurgical patients. In the present study the effect of dihydralazine on the diameters of pial arteries and veins was measured in the cat through a closed cranial window. ICP was concomitantly recorded from a needle in the cisterna magna.
Material and Methods
Thirteen experiments were performed in 11 cats with a body weight of 2-3.4 kg. The cats were anesthetized with 40 mg • kg 1 electromanomcter and recorded with a Rikadenki 2-channel writer. EKG and pulse frequency were continuously monitored with a Philips unit. Paco, and Pad were frequently measured in an AVL gas check and maintained on normal and stable levels (Paco, 25-35 mm Hg). Body temperature was controlled by a Philips rectal thermosensor unit and maintained during the experiments between 37 and 38°C by aid of a heating pad. The head was fixed in a stereotaxic holder and a parasagittal parietal window inserted. A modification of the technique described by Forbes was used. 4 ' • Pial vessels were observed through the closed cranial window with the aid of a Leitz intravital microscope. Diameter variations were measured with a multichannel videoangiometer, 8 or by aid of an image splitting eyepiece every 15 seconds within the first minute, every 30 seconds during the following 4 minutes and, later, every minute until the end of the experiment.
Dihydralazine, 250 n% • kg" 1 , was given intravenously in 6 experiments to 4 cats, and venular diameters were then recorded for 15-20 minutes. Seven other cats were given 1 mg • kg" 1 dihydralazine. In these experiments both the diameters of veins and arteries were recorded. ICP was monitored in 5 of the cats by inserting a needle into the cisterna magna and connecting it to a Statham P23dB transducer and a second Hellige unit. Statistical evaluation was performed with the Wilcoxon signed rank test.
Results MAP, ICP and vascular diameters are given in the table. Figure 1 shows the mean value curve of MAP and venous diameter reactions after injection of 250 ng • kg 1 . All arterial vessels studied, i.e. 8 vessels with resting diameter 49-102 nm, reacted with a pronounced dilatation (p < 0.01) after injection of 1 mg • kg 1 dihydralazine. The diameters of the veins were essentially unchanged, whereas ICP increased by 95% within 7 minutes ( 1 -a The maximum change in arterial diameter was reached somewhat later than the maximum increase in ICP but earlier than the lowest blood pressure levels.
The dilatation obtained after dihydralazine administration far exceeds that seen as a result of autoregulation with a corresponding reduction in blood pressure. In a recent study, briefly reported by Johansson et al., T 10 arteries from 8 cats were measured with the same technique as in the present study during hypotension induced by withdrawal of blood. Lowering of MAP from 121 ± 24 (SD) mm Hg to 68 ± 3.5 mm Hg, i.e. a 44% decrease in pressure, reduced the diameter of arterial vessels with an initial diameter 46-184 nm by 10% only. This is in agreement with the classical study by Fog* whose data showed that arterioles with a resting diameter of 32-57 Mm increased 11% (range 9-22%) when MAP was lowered from 80-110 to 70-85 mm Hg by bleeding (mean decrease 18%). [Data taken from Table V e also using a cranial window technique, reported that only arteries with diameter > 200 fim dilated within the pressure range of MAP 110-160 mm Hg; arteries < 200 ^m started to dilate below 110 mm Hg and vessels < 75 pm did not dilate until MAP decreased below 90 mm Hg. However, it can not be excluded that the lack of responsiveness of smaller arteries in their study could be associated with the fact that they kept the intracranial pressure constant which is likely to influence the hemodynamics of the microvessels. The above quoted results show that the dilatation of pial arteries within the autoregulatory range is of a much lower magnitude than the 50% increase of diameter obtained in our study with a moderate lowering of MAP. It seems fair to conclude that dihydralazine is, to a large extent, responsible for the dilatation in the present study.
Antihypertensive drugs have been studied surprisingly little for their effects on the cerebral circulation. It seems possible that dihydralazine, because of the increase in ICP, can be hazardous to patients with preexisting intracranial hypertension.' In addition to an effect on ICP, the vasodilatory action per se can be potentially harmful, particularly when it occurs earlier than the decrease in systemic MAP. Dilatation enhances pressure-induced extravasation of protein into the brain and results in leakage at lower pressure levels.
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u Even if results obtained from animals with intact cerebral circulation obviously cannot be directly applied to patients with cerebrovascular disease, it should theoretically be better to decrease the blood pressure with drugs that do not preferentially dilate cerebral resistance vessels in patients with manifest or suspect increase of ICP.
